brd4 Antibody

What is BRD4 and why is it an important research target?

BRD4 belongs to the BET (Bromodomain and Extra-Terminal) family of proteins characterized by two N-terminal bromodomains and one Extra Terminal (ET) domain. BRD4 functions as an epigenetic "reader" by recognizing acetylated histone lysine residues through its bromodomains, regulating chromatin structure and gene expression. It has been identified as a therapeutic target in numerous cancers including acute myeloid leukemia, multiple myeloma, Burkitt's lymphoma, NUT midline carcinoma, colon cancer, and breast cancer. BRD4 also regulates transcription of oncogenes, HIV, and human papilloma virus (HPV), and can bind and phosphorylate RNA polymerase II, implicating its involvement in eukaryotic transcription regulation .

What criteria should researchers consider when selecting a BRD4 antibody?

When selecting a BRD4 antibody, researchers should consider:

• Validated specificity: Choose antibodies validated with knockout controls or multiple detection methods

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, ICC/IF, ChIP)

• Species reactivity: Verify reactivity with your experimental organism (human, mouse, etc.)

• Isoform recognition: Determine if the antibody recognizes specific BRD4 isoforms

• Clonality: Consider whether monoclonal specificity or polyclonal broader epitope recognition is preferable

• Host species: Select a host species compatible with your experimental system

• KD (affinity) values: Higher affinity generally correlates with better sensitivity

Recombinant antibodies like EPR5150(2) typically offer 1-2 orders of magnitude higher affinity compared to traditional monoclonal antibodies, providing superior batch-to-batch consistency .

What is the difference between monoclonal and polyclonal BRD4 antibodies?

For critical quantitative studies requiring reproducibility, recombinant monoclonal antibodies provide superior consistency. For applications requiring enhanced signal or multiple epitope recognition, polyclonal antibodies may be advantageous .

What are the optimal methods for using BRD4 antibodies in Western blotting?

For optimal Western blot results with BRD4 antibodies:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • Load 10-20 μg of total protein for cell lines (as used with ab128874)

• Gel selection and transfer:

  • Use gradient gels (4-12%) to resolve the high molecular weight BRD4 (~152-200 kDa)

  • Ensure complete transfer using low SDS buffer and longer transfer times

• Antibody dilution and incubation:

  • Primary antibody dilutions vary by product:

    • ab128874: 1/200-1/1000

    • 28486-1-AP: 1/1000-1/4000

  • Incubate at 4°C overnight for optimal results

• Expected molecular weight:

  • Although the calculated molecular weight is 152 kDa, BRD4 typically appears at higher weights (200-220 kDa) due to post-translational modifications

  • Validate specificity with knockout/knockdown controls as demonstrated with HAP1 wildtype vs. BRD4 knockout cells

• Blocking conditions:

  • 5% non-fat dry milk in TBST works well for many BRD4 antibodies

How can researchers optimize BRD4 antibodies for immunofluorescence applications?

For optimal immunofluorescence with BRD4 antibodies:

• Fixation and permeabilization:

  • 4% paraformaldehyde (10 min at room temperature) followed by permeabilization with either:

    • 0.2% Triton X-100 (10 min) , or

    • 0.1% Triton X-100 (time optimized for cell type)

• Antibody dilution:

  • EPR5150(2) (ab128874): 1/100-1/500

  • 28486-1-AP: 1/300-1/1200

• Nuclear co-localization:

  • BRD4 typically shows nuclear localization

  • DAPI counterstain helps visualize nuclear co-localization

  • For co-localization studies, BRD4 has been successfully paired with CDK9 staining

• Signal amplification:

  • For weaker signals, consider using fluorophore-conjugated secondary antibodies with higher signal-to-noise ratios

  • Fluorophores like Alexa Fluor 488 have been successfully used with BRD4 antibodies

• Controls:

  • Include secondary-only controls to assess background

  • Consider knockdown/knockout samples when available

What protocols give the best results for BRD4 chromatin immunoprecipitation (ChIP)?

Although specific ChIP protocols aren't directly presented in the search results, based on general principles and BRD4's function:

• Crosslinking optimization:

  • Standard: 1% formaldehyde for 10 minutes at room temperature

  • For BRD4 interactions with acetylated histones, dual crosslinking with 1.5 mM EGS followed by formaldehyde may improve yield

• Sonication parameters:

  • Optimize to achieve chromatin fragments between 200-500 bp

  • BRD4 ChIP often requires more extensive sonication than standard histone ChIP

• Antibody selection and amounts:

  • Use ChIP-validated antibodies (many antibodies work in WB/IHC but fail in ChIP)

  • Typically 2-5 μg antibody per ChIP reaction

• Controls and validation:

  • IgG negative control is essential

  • Perform qPCR validation at known BRD4 binding sites (e.g., MYC enhancers)

  • Consider spike-in normalization for quantitative comparisons between conditions

• Suggested wash conditions:

  • Low salt wash (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl)

  • High salt wash (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM NaCl)

  • LiCl wash (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl)

  • TE buffer wash

How can researchers address non-specific binding when using BRD4 antibodies?

To address non-specific binding with BRD4 antibodies:

• Validate antibody specificity:

  • Confirm specificity using knockout/knockdown controls as demonstrated with ab128874 in HAP1 wildtype vs. BRD4 knockout cell lines

  • The observed band size for BRD4 (typically 200-220 kDa) can differ from the calculated molecular weight (152 kDa)

• Optimize blocking conditions:

  • For Western blot: Test different blocking agents (5% BSA vs. 5% non-fat dry milk)

  • For IF/IHC: Include serum matching the host of the secondary antibody (e.g., goat serum for goat anti-rabbit secondary)

• Adjust antibody concentrations:

  • Titrate primary antibody to find optimal signal-to-noise ratio

  • For Western blot, start with recommended dilutions:

    • ab128874: 1/200-1/1000

    • 28486-1-AP: 1/1000-1/4000

• Increase washing stringency:

  • Increase washing steps (number and duration)

  • For problematic background, consider adding 0.1-0.5% SDS to wash buffers

• Pre-absorb antibodies:

  • For cross-reactive antibodies, pre-absorb with cell/tissue lysates from BRD4-knockout samples

What are the challenges in detecting different BRD4 isoforms and how can they be overcome?

• Background on BRD4 isoforms:

  • Multiple isoforms exist, with the two major isoforms being:

    • Long isoform (~200 kDa): Contains C-terminal domain (CTD) important for P-TEFb interaction

    • Short isoform (~140 kDa): Lacks the CTD

• Isoform-specific detection challenges:

  • Many antibodies detect both major isoforms

  • Distinguishing isoforms requires careful gel resolution and antibodies targeting specific domains

• Strategies for isoform discrimination:

  • Use gradient gels (4-12%) with extended run times to clearly separate isoforms

  • Select antibodies raised against N-terminal (detects all isoforms) vs. C-terminal epitopes (detects only long isoform)

  • Compare with recombinant standards of known isoforms

  • Use isoform-specific knockdown/overexpression controls

• Expected banding patterns:

  • Long isoform: Typically observed at ~200-220 kDa

  • Short isoform: Usually observed at ~140-150 kDa

  • Additional bands may represent post-translationally modified forms

• Verification techniques:

  • Use knockout/knockdown followed by rescue experiments with specific isoforms

  • Mass spectrometry analysis to confirm isoform identity

What are the best practices for storage and handling of BRD4 antibodies to maintain long-term activity?

Best practices:

• Follow manufacturer's specific recommendations

• For antibodies without glycerol, consider adding glycerol (final 30-50%) for freeze protection

• Store in small working aliquots to minimize freeze-thaw cycles

• Avoid repeated freezing and thawing

• Centrifuge briefly after thawing to collect contents at the bottom of the tube

How can BRD4 antibodies be effectively used in research on BRD4 inhibitors and drug resistance mechanisms?

• Monitoring BRD4 occupancy changes:

  • ChIP-seq with BRD4 antibodies before and after inhibitor treatment can map genome-wide displacement patterns

  • BRD4 antibodies can confirm target engagement in cell-based models

• Resistance monitoring protocols:

  • Western blot with BRD4 antibodies to detect expression changes in resistant cells

  • Pull-down assays to assess altered protein-protein interactions in resistant cells

  • ChIP analysis to identify altered chromatin occupancy patterns

• Combination therapy research:

  • BRD4 antibodies in co-IP experiments can identify altered protein complexes

  • Western blot analysis of downstream effectors can reveal pathway adaptation

• Evaluating bromodomain-independent functions:

  • Use BRD4 antibodies recognizing different domains to distinguish between bromodomain-dependent and independent functions

  • Co-IP experiments can identify interactions that persist despite BET inhibitor treatment

• Recommended controls:

  • Include genetically engineered BRD4 mutants resistant to inhibitor binding

  • Compare acute vs. chronic inhibitor exposure

  • Include gene knockout/knockdown samples alongside inhibitor treatment

What are the key considerations when using BRD4 antibodies for studying post-translational modifications (PTMs) of BRD4?

• Known BRD4 PTMs:

  • Phosphorylation: BRD4 can be phosphorylated by CK2, which affects its chromatin binding properties

  • Acetylation: BRD4 itself can be acetylated, creating a potential auto-regulatory mechanism

  • Ubiquitination: Regulates BRD4 stability and turnover

• Antibody selection for PTM studies:

  • Use PTM-specific antibodies (phospho-BRD4, acetyl-BRD4) when available

  • For general BRD4 detection in PTM studies, select antibodies whose epitope doesn't overlap with the modification site

• Experimental design considerations:

  • Include phosphatase inhibitors in lysis buffers when studying phosphorylation

  • Include deacetylase inhibitors (e.g., TSA, nicotinamide) when studying acetylation

  • Include proteasome inhibitors (e.g., MG132) when studying ubiquitination

  • Consider 2D gel electrophoresis to resolve differentially modified forms

• Validation approaches:

  • Use mass spectrometry to confirm modification sites

  • Generate site-specific mutants (e.g., S→A for phosphorylation, K→R for acetylation/ubiquitination)

  • Employ specific modifying or demodifying enzymes as controls

• Technical challenges:

  • Modified forms may represent a small fraction of total BRD4

  • Enrichment steps (immunoprecipitation) may be necessary before detection

  • Different PTMs may affect antibody recognition, requiring careful validation

How can BRD4 antibodies be applied in research on disease-specific BRD4 functions?

BRD4 antibodies can be applied to disease-specific research in several sophisticated ways:

• Cancer-specific applications:

  • BRD4 has been identified as a therapeutic target in numerous cancer types, including "acute myeloid leukemia, multiple myeloma, Burkitt's lymphoma, NUT midline carcinoma, colon cancer, and breast cancer"

  • ChIP-seq using validated BRD4 antibodies can map cancer-specific enhancer occupancy

  • Co-IP experiments can identify cancer-specific protein interaction partners

  • IHC with BRD4 antibodies on cancer tissue microarrays can establish expression patterns and correlation with clinicopathological features

• Viral infection studies:

  • Given BRD4's role in regulating "transcription of oncogenes, HIV, and human papilloma virus (HPV)" :

  • IF/ICC with BRD4 antibodies can reveal redistribution during viral infection

  • ChIP analysis can map BRD4 recruitment to viral genomes

  • Co-IP can identify viral proteins that interact with BRD4

• Tissue-specific methodologies:

  • For FFPE samples: Use BRD4 antibodies validated for IHC on fixed tissues with appropriate antigen retrieval

  • For frozen tissue sections: Optimize fixation conditions (typically 4% PFA)

  • For tissue-specific ChIP: Adapt chromatin preparation protocols to specific tissue types

• Developmental biology applications:

  • The Drosophila BRD4 homolog is related to "female Sterile Homeotic protein gene in Drosophila, a gene required maternally for proper expression of other homeotic genes, such as Ubx, which is involved in pattern formation"

  • Use species-appropriate BRD4 antibodies for developmental stage-specific analyses

  • IHC to map expression patterns during development

  • ChIP-seq to identify developmental stage-specific binding sites

How should researchers validate BRD4 antibody specificity for their specific experimental system?

• Genetic validation approaches:

  • BRD4 knockout controls: ab128874 has been validated using HAP1 wildtype vs. BRD4 knockout cell lysates, showing band elimination in knockout samples

  • siRNA/shRNA knockdown: Demonstrate proportional signal reduction

  • Rescue experiments: Restore signal with exogenous BRD4 expression

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Should abolish specific signal in all applications

• Multi-antibody validation:

  • Use multiple antibodies targeting different BRD4 epitopes

  • Compare signal patterns across different applications

• Expected patterns as validation:

  • Western blot: Major band at 200-220 kDa (despite calculated MW of 152 kDa)

  • IF/ICC: Predominantly nuclear localization

  • IHC: Nuclear staining pattern consistent with transcription factor function

• Application-specific controls:

  • For WB: Include positive control lysates (HeLa, A549, Jurkat cells show reliable expression)

  • For IF: Include secondary-only controls to assess background

  • For ChIP: Include IgG controls and positive/negative region controls

What approaches can resolve conflicting results between different BRD4 antibodies?

• Systematic comparison methodology:

  • Document exact protocols used with each antibody

  • Test antibodies side-by-side under identical conditions

  • Compare results against known BRD4 biology (nuclear localization, expected MW)

• Epitope mapping considerations:

  • Determine epitope locations for each antibody

  • N-terminal vs. C-terminal epitopes may detect different isoforms

  • Certain epitopes may be masked by protein-protein interactions or PTMs

• Validation hierarchy approach:

  • Prioritize results from antibodies with:

    1. Knockout/knockdown validation

    2. Multiple application validation

    3. Citations in peer-reviewed literature

    4. Recombinant formats with batch consistency

• Resolution strategies for specific conflicts:

  • Different molecular weights: May indicate isoforms or PTMs

  • Different subcellular localization: May reflect fixation differences or cell state

  • Different ChIP profiles: May indicate epitope accessibility issues

• Independent validation methods:

  • Tagged BRD4 expression (FLAG, HA, GFP)

  • Mass spectrometry identification

  • Functional assays (e.g., BRD4 inhibitor sensitivity)

How can researchers accurately quantify BRD4 levels in different experimental conditions?

• Western blot quantification best practices:

  • Include loading controls optimized for BRD4's high molecular weight (e.g., vinculin)

  • Use fluorescent secondary antibodies for wider linear range

  • Run standard curves with known quantities of recombinant BRD4

  • Normalize to total protein rather than single housekeeping genes

• RT-qPCR methodology:

  • Design primers specific to different BRD4 isoforms

  • Validate primer efficiency with standard curves

  • Use multiple reference genes for normalization

  • Consider absolute quantification with in vitro transcribed standards

• Flow cytometry approaches:

  • Optimize fixation and permeabilization for nuclear protein detection

  • Include fluorescence-minus-one (FMO) controls

  • Use median fluorescence intensity (MFI) for quantification

  • Consider dual staining with cell cycle markers

• Advanced quantitative techniques:

  • Selected Reaction Monitoring (SRM) or Parallel Reaction Monitoring (PRM) mass spectrometry

  • Digital droplet PCR for absolute transcript quantification

  • Quantitative immunofluorescence with automated image analysis

• Addressing experimental variabilities:

  • Biological replicates should be from independent experiments

  • Technical replicates should use independently prepared samples

  • Standardize cell confluence/density/passage number

  • Document and control for treatment time and conditions